Attorney Erin Copeland, partner of Fibich, Leebron, Copeland & Briggs has recently been appointed to the Essure Executive Committee for California as a Judicial Council Coordinate Proceeding (JCCP). Erin has been a prominent leader in the fight against Essure and often speaks out about the dangers of this risky medical device. Essure is a birth control device made out of nickel and titanium, which is implanted into a woman’s fallopian tubes to block sperm, thereby preventing pregnancy.
The FDA reported that over 9,000 women submitted voluntary complaints against Essure. Many of the complications reported about the device include ectopic pregnancy, fetal death, additional surgeries, and hysterectomies to remove Essure and repair organs. Despite Bayer’s denial of any wrongdoing, the device was given a black box warning by the FDA, indicating that the product may cause serious injuries or death. It is the FDA’s highest warning level.
Attorney Erin Copeland is one of five attorneys appointed to the Essure Executive Committee to lead the pretrial proceedings on behalf of all plaintiffs in the California coordinated litigation Essure Product Cases. The Executive Committee is comprised of: Fidelma Fitzpatrick of Motley Rice; Kim Dougherty; M. Elizabeth Graham of Grant & Eisenhofer P.A.; Edward A. Wallace of Wexler Wallace LLP. Fidelma Fitzpatrick will chair the Executive Committee. M. Elizabeth Graham and William A. Kershaw of Kershaw, Cook & Talley will act as co-liaisons.
Read the full press release here.